[ad_1]
The US Food and Drug Administration has granted the drug an "expedited review", which could significantly reduce the time to obtain approval for its use there. Australia
Kara and Richard Nell of Perth lost their three-year-old son Kai to AML, who fought the disease for most of his life
In a video produced for Race Oncology, Ms. Nell said that They had looked for "
" It is hope, because for us, when we brought it home, we had no hope, trawler l & # 39; 39, Internet, talk to oncologists, there was still no hope. she said.
"And to hear that there is potentially something that could work for these children, so just that hope … it matters to every child who is affected by a rare type of cancer."
The drug itself has been around for decades, but had languished after a number of Mpany co-mergers, and was tested in clinical trials in the 1980s and 1990s that showed some success. As the FDA process begins, Mr. Molloy said that Race would seek to "develop and run a clinical trial in children with AML to demonstrate the effectiveness of Bisantrene."
Source link
